Comparison of outcomes of unrelated bone marrow and umbilical cord blood transplants in children with acute leukemia.

Blood
V RochaE Gluckman

Abstract

In order to compare the outcomes of unrelated umbilical cord blood transplants (UCBTs) or bone marrow transplants, 541 children with acute leukemia (AL) transplanted with umbilical cord blood (n = 99), T-cell-depleted unrelated bone marrow transplants (T-UBMT) (n = 180), or nonmanipulated (UBMT) (n = 262), were analyzed in a retrospective multicenter study. Comparisons were performed after adjustment for patient, disease, and transplant variables. The major difference between the 3 groups was the higher number in the UCBT group of HLA mismatches (defined by serology for class I and molecular typing for DRB1). The donor was HLA mismatched in 92% of UCBTs, in 18% of UBMTs, and in 43% of T-UBMTs (P <.001). Other significant differences were observed in pretransplant disease characteristics, preparative regimens, graft-versus-host disease (GVHD) prophylaxis, and number of cells infused. Nonadjusted estimates of 2-year survival and event-free survival rates were 49% and 43%, respectively, in the UBMT group, 41% and 37% in the T-UBMT group, and 35% and 31% in the UCBT group. After adjustment, differences in outcomes appeared in the first 100 days after the transplantation. Compared with UBMT recipients, UCBT recipients had delayed he...Continue Reading

Associated Clinical Trials

Citations

Sep 7, 2002·International Journal of Hematology·Hitomi NagayamaAsano Shigetaka
May 29, 2010·Annals of Hematology·Hyoung Jin KangHyo Seop Ahn
Nov 19, 2004·Springer Seminars in Immunopathology·Eliane Gluckman, Vanderson Rocha
Sep 1, 2006·Current Hematologic Malignancy Reports·Demetrios Petropoulos, Ka Wah Chan
Oct 14, 2005·Current Oncology Reports·Demetrios Petropoulos, Ka Wah Chan
Jan 24, 2007·Stem Cell Reviews·Richard L Haspel, Karen K Ballen
Dec 4, 2010·Immunologic Research·Paul Szabolcs
Oct 21, 2004·Best Practice & Research. Clinical Haematology·John McCarty
Jun 7, 2005·Human Immunology·M Brigid Bradley, Mitchell S Cairo
Mar 2, 2002·Human Immunology·A SlavcevB S Breur-Vriesendorp
Jun 9, 2004·Blood Reviews·Yossi Cohen, Arnon Nagler
Mar 14, 2003·Cancer Treatment Reviews·Uday PopatHelen E Heslop
Oct 31, 2003·Critical Reviews in Oncology/hematology·Juliet N Barker, John E Wagner
Aug 14, 2001·Transfusion clinique et biologique : journal de la Société française de transfusion sanguine·E GluckmanS Chevret
Jul 24, 2008·Bone Marrow Transplantation·F LocatelliF Moretta
Jul 24, 2008·Bone Marrow Transplantation·C MessinaUNKNOWN EBMT Paediatric Working Party
Jul 24, 2008·Bone Marrow Transplantation·A SchrauderUNKNOWN I-BFM Study Group
Jul 24, 2008·Bone Marrow Transplantation·E LaninoUNKNOWN Eurocord
Jul 24, 2008·Bone Marrow Transplantation·E GluckmanUNKNOWN Eurocord
Oct 6, 2009·Bone Marrow Transplantation·E Gluckman
Oct 6, 2009·Bone Marrow Transplantation·C G Brunstein, D J Weisdorf
Oct 6, 2009·Bone Marrow Transplantation·V K Prasad, J Kurtzberg
Oct 6, 2009·Bone Marrow Transplantation·V RochaE Gluckman
Dec 17, 2009·Bone Marrow Transplantation·M AyasH El-Solh
Jun 27, 2012·Bone Marrow Transplantation·B C Beaudette-ZlatanovaP J Stiff
Jul 19, 2012·Leukemia·J KandaUNKNOWN Donor/Source Working Group and HLA Working Group of the Japan Society for Hematopoietic Cell Transplantation
Jul 2, 2003·Nature Reviews. Cancer·Juliet N Barker, John E Wagner
Jun 13, 2008·Nature Reviews. Cancer·Michael J Sullivan

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.